Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
Authors:
- 9 August 2024
- journal article
- letter
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (10) , 1869-1870
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Undiagnosed vertebral fragility fractures in patients with distal radius fragility fractures: an opportunity for prevention of morbimortality in osteoporotic patients in developing countriesOsteoporosis International, 2024
- A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosisOsteoporosis International, 2024
- Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational studyJBMR Plus, 2024
- Romosozumab and antiresorptive treatment: the importance of treatment sequenceOsteoporosis International, 2022
- Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical TrialJournal of Bone and Mineral Research, 2020
- Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTSThe Journal of Clinical Endocrinology & Metabolism, 2020
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for OsteoporosisJournal of Bone and Mineral Research, 2016
- Teriparatide and denosumab combination therapy and skeletal metabolismOsteoporosis International, 2016